Ena Respiratory Company
%20.jpg)
Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.
Technology:
diagnostics
Headquarters:
Melbourne, Victoria, Australia
Funding Status:
Early Stage Venture
Founded Date:
41640
Last Funding Type:
Series A
Last Funding Date:
2020-09-28
Estimated Revenue:
$1M to $10M
Employee Number:
11-50
Industry:
Biotechnology, Health Diagnostics, Medical